Consumer perceptions of legal cannabis products in Canada, 2019-2021: a repeat cross-sectional study.
Cannabis
Legalization
Marijuana
Perceptions
Price
Safety
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
08 11 2022
08 11 2022
Historique:
received:
06
07
2022
accepted:
31
10
2022
entrez:
9
11
2022
pubmed:
10
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Consumer perceptions of legal cannabis products may drive willingness to purchase from the illegal or legal market; however, little is known on this topic. The current study examined perceptions of legal products among Canadian cannabis consumers over a 3-year period following federal legalization of non-medical cannabis in 2018. Data were analyzed from Canadian respondents in the International Cannabis Policy Study, a repeat cross-sectional survey conducted in 2019-2021. Respondents were 15,311 past 12-month cannabis consumers of legal age to purchase cannabis. Weighted logistic regression models examined the association between perceptions of legal cannabis and province of residence, and frequency of cannabis use over time. In 2021, cannabis consumers perceived legal cannabis to be safer to buy (54.0%), more convenient to buy (47.8%), more expensive (47.2%), safer to use (46.8%) and higher quality (29.3%) than illegal cannabis. Except for safety of purchasing, consumers had more favourable perceptions of legal cannabis in 2021 than 2019 across all outcomes. For example, consumers had higher odds of perceiving legal cannabis as more convenient to buy in 2021 than 2019 (AOR = 3.09, 95%CI: 2.65,3.60). More frequent consumers had less favourable perceptions of legal cannabis than less frequent consumers. Three years since legalization, Canadian cannabis consumers generally had increasingly favourable perceptions of legal vs. illegal products - except for price - with variation across the provinces and frequency of cannabis use. To achieve public health objectives of legalization, federal and provincial governments must ensure that legal cannabis products are preferred to illegal, without appealing to non-consumers.
Sections du résumé
BACKGROUND
Consumer perceptions of legal cannabis products may drive willingness to purchase from the illegal or legal market; however, little is known on this topic. The current study examined perceptions of legal products among Canadian cannabis consumers over a 3-year period following federal legalization of non-medical cannabis in 2018.
METHODS
Data were analyzed from Canadian respondents in the International Cannabis Policy Study, a repeat cross-sectional survey conducted in 2019-2021. Respondents were 15,311 past 12-month cannabis consumers of legal age to purchase cannabis. Weighted logistic regression models examined the association between perceptions of legal cannabis and province of residence, and frequency of cannabis use over time.
RESULTS
In 2021, cannabis consumers perceived legal cannabis to be safer to buy (54.0%), more convenient to buy (47.8%), more expensive (47.2%), safer to use (46.8%) and higher quality (29.3%) than illegal cannabis. Except for safety of purchasing, consumers had more favourable perceptions of legal cannabis in 2021 than 2019 across all outcomes. For example, consumers had higher odds of perceiving legal cannabis as more convenient to buy in 2021 than 2019 (AOR = 3.09, 95%CI: 2.65,3.60). More frequent consumers had less favourable perceptions of legal cannabis than less frequent consumers.
CONCLUSIONS
Three years since legalization, Canadian cannabis consumers generally had increasingly favourable perceptions of legal vs. illegal products - except for price - with variation across the provinces and frequency of cannabis use. To achieve public health objectives of legalization, federal and provincial governments must ensure that legal cannabis products are preferred to illegal, without appealing to non-consumers.
Identifiants
pubmed: 36348479
doi: 10.1186/s12889-022-14492-z
pii: 10.1186/s12889-022-14492-z
pmc: PMC9644504
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2048Informations de copyright
© 2022. The Author(s).
Références
Int J Drug Policy. 2020 Feb;76:102658
pubmed: 31927413
Addict Behav. 2021 Jan;112:106563
pubmed: 32768793
PLoS One. 2015 Nov 25;10(11):e0143562
pubmed: 26605550
Lancet. 2007 Jul 28;370(9584):319-28
pubmed: 17662880
Drug Alcohol Depend. 2007 Sep;90 Suppl 1:S61-8
pubmed: 16971056
Drug Alcohol Depend. 2013 Dec 1;133(2):352-9
pubmed: 23886472
Drug Alcohol Depend. 2017 Jan 01;170:174-180
pubmed: 27951424
Int J Environ Res Public Health. 2022 Feb 23;19(5):
pubmed: 35270255
Drug Alcohol Depend. 2022 Feb 1;231:109262
pubmed: 34998249
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64
pubmed: 22927402
Addict Behav. 2019 Mar;90:402-408
pubmed: 30530299
Drug Alcohol Rev. 2022 Feb;41(2):377-385
pubmed: 34250645
Drug Alcohol Rev. 2022 Jul;41(5):1131-1135
pubmed: 35316855
Drug Alcohol Depend. 2021 Aug 1;225:108794
pubmed: 34098382
Drug Test Anal. 2014 Jan-Feb;6(1-2):39-45
pubmed: 23836598
Drug Alcohol Rev. 2020 May;39(4):337-346
pubmed: 32291811
Addiction. 2013 Jan;108(1):124-33
pubmed: 22775447
Int J Drug Policy. 2020 Feb 26;77:102698
pubmed: 32113149
Drug Alcohol Depend. 2021 Nov 1;228:109071
pubmed: 34592703
Lancet Psychiatry. 2019 May;6(5):427-436
pubmed: 30902669
Public Health Rev. 2014;35(2):1-18
pubmed: 25642015
J Stud Alcohol Drugs. 2022 May;83(3):392-401
pubmed: 35590180
Health Rep. 2021 Apr 21;32(4):3-14
pubmed: 33881274
Addiction. 2015 Jan;110(1):19-35
pubmed: 25287883
Psychol Med. 2012 Jun;42(6):1321-8
pubmed: 21999906